LY225910

• Catalog No.: L2545
• CAS Number: 133040-77-4
• M. F.: C27H24BrN3O2
• M. W.: 502.40236
• Purity: ≥98% (HPLC)

SYNONYMS

• IUPAC name: 2-[2-(5-bromo-1H-indol-3-yl)ethyl]-3-[3-(propan-2-yloxy)phenyl]-3,4-dihydroquinazolin-4-one
• IUPAC Traditional name: 2-[2-(5-bromo-1H-indol-3-yl)ethyl]-3-(3-isopropoxyphenyl)quinazolin-4-one
• Synonyms: 2-[2-(5-Bromo-1H-indol-3-yl)ethyl]-3-[3-(1-methylethoxy )phenyl]-4-(3H)-quinazolinone

DATABASE IDS

• MDL Number: MFCD00907856
• CAS Number: 133040-77-4

PROPERTIES

• Empirical Formula (Hill Notation): C27H24BrN3O2
• Purity: ≥98% (HPLC)
• Apperance: off-white powder
• Flash Point: 337 - 405 °C
• Flash Point: 638.6 - 761 °F
• Solubility: DMSO: >20 mg/mL
• GHS Signal Word: Danger
• GHS Hazard statements: H301-H413
• European Hazard Symbols: Harmful (Xn)
• GHS Precautionary statements: P301 + P310
• RID/ADR: UN 2811 6.1/PG 3
• Risk Statements: 22
• Storage Temperature: 2-8°C
• Hazard Class: 6.1
• UN Number: 2811
• Packing Group: 3
• German water hazard class: 3

DETAILS

Description (English)

Biochem/physiol Actions
Cholecystokinin is expressed in the gastrointestinal tract and the central nervous system. Cholecystokinin receptor type 2 (CCK2) is a GPCR that is highly expressed in brain and spinal cord. CCK2 is implicated in many brain processes, including mood, anxiety, and pain, through its modulation of GABA neurotransmission.LY225910 is a potent, selective CCK2 antagonist. LY225910 blocks agonism of CCK2 by CCK-8S, the peptide agonist. LY225910 has been measured in multiple systems, including GABA efflux from cortical cultures, depolarization of spinal cord neurons (via potassium conductance), modulation of excitatory postsynaptic potentials (EPSPs) in nucleus accumbens slices, and enhancement of morphine analgesia.

Description (简体中文)

Biochem/physiol Actions
Cholecystokinin is expressed in the gastrointestinal tract and the central nervous system. Cholecystokinin receptor type 2 (CCK2) is a GPCR that is highly expressed in brain and spinal cord. CCK2 is implicated in many brain processes, including mood, anxiety, and pain, through its modulation of GABA neurotransmission.LY225910 is a potent, selective CCK2 antagonist. LY225910 blocks agonism of CCK2 by CCK-8S, the peptide agonist. LY225910 has been measured in multiple systems, including GABA efflux from cortical cultures, depolarization of spinal cord neurons (via potassium conductance), modulation of excitatory postsynaptic potentials (EPSPs) in nucleus accumbens slices, and enhancement of morphine analgesia.